New eye injection shows promise for Diabetes-Related vision loss
NCT ID NCT06908876
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new eye injection called IBI302 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. About 150 adults aged 18-80 with type 1 or 2 diabetes and swelling in the center of the retina will receive either IBI302 or an active control. The main goal is to see if IBI302 improves vision and reduces eye swelling over 16 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General hospital
Shanghai, Shanghai Municipality, 200080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection preserve vision in south asians with diabetes?
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?
- Can a steroid implant boost the effect of standard eye injections for hard-to-treat diabetic macular edema?
- Eye injection aims to tame leading causes of blindness
- New eye drug aims to restore vision in Diabetes-Related swelling